See more : PAR Technology Corporation (PAR) Income Statement Analysis – Financial Results
Complete financial analysis of Thermo Fisher Scientific Inc. (TMO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Thermo Fisher Scientific Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- enX Group Limited (ENX.JO) Income Statement Analysis – Financial Results
- Chengdu Zhimingda Electronics Co., Ltd. (688636.SS) Income Statement Analysis – Financial Results
- Avant Technologies Inc. (AVAI) Income Statement Analysis – Financial Results
- Birman Wood & Hardware Ltd (BIRM.TA) Income Statement Analysis – Financial Results
- Convano Inc. (6574.T) Income Statement Analysis – Financial Results
Thermo Fisher Scientific Inc. (TMO)
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.86B | 44.92B | 39.21B | 32.22B | 25.54B | 24.36B | 20.92B | 18.27B | 16.97B | 16.89B | 13.09B | 12.51B | 11.73B | 10.79B | 10.11B | 10.50B | 9.75B | 3.79B | 2.63B | 2.21B | 2.10B | 2.09B | 2.19B | 2.28B | 2.47B | 3.87B | 3.56B | 2.93B | 2.21B | 1.59B | 1.25B | 949.00M | 805.50M | 708.00M | 579.00M | 500.60M | 383.40M | 331.60M | 265.70M |
| Cost of Revenue | 25.74B | 25.42B | 18.98B | 15.71B | 13.72B | 12.99B | 10.96B | 9.46B | 8.78B | 8.97B | 7.34B | 6.99B | 6.74B | 6.22B | 5.96B | 6.29B | 5.94B | 2.22B | 1.44B | 1.19B | 1.15B | 1.16B | 1.23B | 1.26B | 1.26B | 2.02B | 1.84B | 1.54B | 1.12B | 866.30M | 713.10M | 579.80M | 510.20M | 443.00M | 384.10M | 325.70M | 248.70M | 219.30M | 174.30M |
| Gross Profit | 17.11B | 19.50B | 20.23B | 16.51B | 11.83B | 11.36B | 9.96B | 8.82B | 8.18B | 7.92B | 5.75B | 5.52B | 4.99B | 4.57B | 4.15B | 4.21B | 3.80B | 1.57B | 1.19B | 1.01B | 948.02M | 927.38M | 958.62M | 1.02B | 1.21B | 1.84B | 1.72B | 1.39B | 1.08B | 719.00M | 536.60M | 369.20M | 295.30M | 265.00M | 194.90M | 174.90M | 134.70M | 112.30M | 91.40M |
| Gross Profit Ratio | 39.93% | 43.42% | 51.60% | 51.23% | 46.30% | 46.65% | 47.60% | 48.24% | 48.23% | 46.89% | 43.93% | 44.10% | 42.54% | 42.39% | 41.04% | 40.07% | 39.03% | 41.36% | 45.38% | 45.99% | 45.21% | 44.45% | 43.81% | 44.81% | 48.81% | 47.65% | 48.36% | 47.40% | 49.05% | 45.35% | 42.94% | 38.90% | 36.66% | 37.43% | 33.66% | 34.94% | 35.13% | 33.87% | 34.40% |
| Research & Development | 1.34B | 1.47B | 1.41B | 1.18B | 1.00B | 967.00M | 888.00M | 754.80M | 692.30M | 691.10M | 395.50M | 376.40M | 340.60M | 287.20M | 246.10M | 249.10M | 238.70M | 170.18M | 152.78M | 134.68M | 146.39M | 155.12M | 171.61M | 176.76M | 171.10M | 367.30M | 337.30M | 0.00 | 269.60M | 103.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.45B | 7.13B | 6.84B | 5.76B | 4.93B | 4.82B | 4.41B | 4.04B | 3.72B | 3.99B | 2.91B | 2.83B | 2.65B | 2.39B | 2.20B | 2.69B | 2.55B | 1.11B | 761.79M | 626.46M | 568.14M | 564.66M | 620.10M | 646.92M | 673.00M | 937.60M | 840.70M | 990.70M | 480.80M | 373.20M | 370.60M | 271.70M | 233.60M | 210.60M | 164.40M | 144.60M | 117.10M | 91.60M | 78.70M |
| Other Expenses | 536.00M | 2.40B | 1.76B | 1.67B | 1.71B | 9.00M | -28.00M | -4.10M | -15.50M | 16.40M | -56.00M | 3.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 113.60M | 162.30M | 135.70M | 115.20M | 85.00M | 62.30M | 42.40M | 29.20M | 23.40M | 18.80M | 12.70M | 11.10M | 10.10M | 8.40M | 7.80M |
| Operating Expenses | 10.24B | 10.99B | 10.01B | 8.61B | 7.65B | 7.53B | 6.89B | 6.18B | 5.73B | 6.01B | 4.06B | 3.95B | 3.64B | 3.25B | 3.04B | 2.94B | 2.79B | 1.28B | 914.56M | 761.14M | 714.53M | 719.78M | 791.72M | 823.68M | 957.70M | 1.47B | 1.31B | 1.11B | 835.40M | 539.20M | 413.00M | 300.90M | 257.00M | 229.40M | 177.10M | 155.70M | 127.20M | 100.00M | 86.50M |
| Cost & Expenses | 36.00B | 36.41B | 28.99B | 24.33B | 21.36B | 20.53B | 17.85B | 15.64B | 14.51B | 14.98B | 11.40B | 10.95B | 10.38B | 9.46B | 9.00B | 9.23B | 8.73B | 3.50B | 2.35B | 1.95B | 1.86B | 1.88B | 2.02B | 2.08B | 2.22B | 3.49B | 3.15B | 2.65B | 1.96B | 1.41B | 1.13B | 880.70M | 767.20M | 672.40M | 561.20M | 481.40M | 375.90M | 319.30M | 260.80M |
| Interest Income | 879.00M | 272.00M | 43.00M | 65.00M | 224.00M | 137.00M | 81.00M | 48.40M | 30.60M | 47.70M | 28.00M | 25.20M | 26.90M | 12.50M | 16.10M | 51.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.38B | 726.00M | 536.00M | 553.00M | 676.00M | 667.00M | 592.00M | 469.60M | 414.90M | 479.90M | 262.10M | 241.60M | 175.30M | 84.70M | 118.10M | 151.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.41B | 3.38B | 2.59B | 2.33B | 2.28B | 2.27B | 2.03B | 1.76B | 1.69B | 1.68B | 999.90M | 983.70M | 863.50M | 770.00M | 787.30M | 792.70M | 756.80M | 240.77M | 123.27M | 66.14M | 58.55M | 56.38M | 98.52M | 97.49M | 113.60M | 162.30M | 135.70M | 115.20M | 85.00M | 62.30M | 42.40M | 29.20M | 23.40M | 18.80M | 12.70M | 11.10M | 10.10M | 8.40M | 7.80M |
| EBITDA | 11.20B | 11.94B | 12.96B | 10.19B | 6.46B | 6.20B | 5.25B | 4.25B | 4.04B | 4.25B | 2.58B | 2.49B | 2.18B | 1.91B | 1.83B | 2.07B | 1.78B | 502.07M | 435.89M | 336.34M | 279.30M | 193.08M | 265.43M | 295.65M | 362.20M | 353.40M | 371.60M | 399.40M | 332.30M | 242.10M | 166.00M | 97.50M | 61.70M | 54.40M | 30.50M | 30.30M | 17.60M | 20.70M | 12.70M |
| EBITDA Ratio | 26.12% | 26.84% | 31.03% | 31.67% | 25.88% | 25.64% | 24.62% | 24.30% | 24.49% | 21.63% | 20.31% | 20.60% | 19.07% | 19.54% | 18.92% | 19.95% | 18.65% | 15.11% | 14.55% | 14.22% | 14.63% | 9.25% | 16.53% | 13.55% | 23.20% | 13.51% | 12.97% | 10.53% | 9.21% | 10.02% | 12.68% | 4.16% | 0.30% | 2.53% | -0.14% | 1.96% | -1.85% | 3.44% | 0.45% |
| Operating Income | 6.86B | 8.39B | 10.03B | 7.79B | 4.59B | 3.78B | 2.97B | 2.45B | 2.34B | 2.50B | 1.61B | 1.48B | 1.25B | 1.26B | 1.05B | 1.23B | 974.40M | 241.96M | 263.49M | 237.51M | 184.77M | 155.45M | 34.20M | 198.16M | 248.60M | 375.80M | 407.00M | 284.20M | 247.30M | 179.80M | 123.60M | 68.30M | 38.30M | 35.60M | 17.80M | 19.20M | 7.50M | 12.30M | 4.90M |
| Operating Income Ratio | 16.00% | 18.69% | 25.57% | 24.19% | 17.99% | 15.53% | 14.19% | 13.40% | 13.77% | 14.82% | 12.30% | 11.85% | 10.62% | 11.72% | 10.38% | 11.71% | 10.00% | 6.38% | 10.01% | 10.77% | 8.81% | 7.45% | 1.56% | 8.69% | 10.06% | 9.72% | 11.44% | 9.69% | 11.20% | 11.34% | 9.89% | 7.20% | 4.75% | 5.03% | 3.07% | 3.84% | 1.96% | 3.71% | 1.84% |
| Total Other Income/Expenses | -561.00M | -558.00M | -1.19B | -567.00M | -524.00M | -521.00M | -531.00M | -434.10M | -399.60M | -415.80M | -290.10M | -212.70M | -112.40M | -100.30M | -121.80M | -79.80M | -93.10M | -32.59M | -7.88M | 4.78M | 35.25M | 131.50M | 42.32M | -23.90M | -230.10M | -28.30M | -100.30M | 17.40M | -8.30M | -7.20M | -13.60M | 19.80M | 33.70M | 15.40M | 16.40M | 8.20M | 15.20M | 4.90M | 6.90M |
| Income Before Tax | 6.30B | 7.84B | 8.84B | 7.23B | 4.07B | 3.26B | 2.43B | 2.02B | 1.94B | 2.09B | 1.32B | 1.27B | 1.13B | 1.16B | 927.10M | 1.15B | 881.30M | 209.37M | 285.90M | 259.22M | 218.63M | 287.99M | 76.52M | 174.26M | 18.50M | 347.50M | 414.00M | 301.60M | 239.00M | 172.60M | 110.00M | 88.10M | 72.00M | 51.00M | 34.20M | 27.40M | 22.70M | 17.20M | 11.80M |
| Income Before Tax Ratio | 14.70% | 17.44% | 22.55% | 22.43% | 15.93% | 13.39% | 11.61% | 11.08% | 11.41% | 12.36% | 10.08% | 10.15% | 9.61% | 10.79% | 9.17% | 10.95% | 9.04% | 5.52% | 10.86% | 11.75% | 10.43% | 13.80% | 3.50% | 7.64% | 0.75% | 8.98% | 11.63% | 10.28% | 10.83% | 10.89% | 8.80% | 9.28% | 8.94% | 7.20% | 5.91% | 5.47% | 5.92% | 5.19% | 4.44% |
| Income Tax Expense | 284.00M | 703.00M | 1.11B | 850.00M | 374.00M | 324.00M | 201.00M | -1.40M | -43.90M | 191.70M | 40.40M | 11.00M | 107.00M | 131.50M | 75.80M | 160.90M | 101.70M | 43.05M | 87.60M | 40.85M | 45.94M | 92.99M | 26.93M | 112.22M | 33.10M | 170.70M | 174.70M | 110.80M | 98.90M | 69.20M | 33.40M | 27.50M | 24.90M | 17.10M | 9.60M | 7.30M | 4.60M | 2.90M | 2.20M |
| Net Income | 6.00B | 6.95B | 7.73B | 6.38B | 3.70B | 2.94B | 2.23B | 2.02B | 1.98B | 1.89B | 1.27B | 1.18B | 1.33B | 1.04B | 850.30M | 994.20M | 761.10M | 168.94M | 223.22M | 361.84M | 200.01M | 309.73M | -781.00K | -36.11M | -174.60M | 181.90M | 239.30M | 190.80M | 140.10M | 103.40M | 76.60M | 59.20M | 47.10M | 33.90M | 24.60M | 20.10M | 18.10M | 14.30M | 9.60M |
| Net Income Ratio | 13.99% | 15.47% | 19.70% | 19.79% | 14.47% | 12.06% | 10.64% | 11.06% | 11.64% | 11.22% | 9.73% | 9.42% | 11.34% | 9.60% | 8.41% | 9.47% | 7.81% | 4.46% | 8.48% | 16.40% | 9.54% | 14.85% | -0.04% | -1.58% | -7.07% | 4.70% | 6.73% | 6.51% | 6.35% | 6.52% | 6.13% | 6.24% | 5.85% | 4.79% | 4.25% | 4.02% | 4.72% | 4.31% | 3.61% |
| EPS | 15.53 | 17.73 | 19.61 | 16.10 | 9.24 | 7.31 | 5.64 | 5.12 | 4.96 | 4.76 | 3.53 | 3.24 | 3.49 | 2.57 | 2.06 | 2.34 | 1.81 | 0.86 | 1.38 | 2.22 | 1.23 | 1.84 | 0.00 | -0.22 | -1.11 | 1.12 | 1.57 | 1.35 | 1.11 | 0.93 | 0.33 | 0.18 | 0.17 | 0.14 | 0.11 | 0.10 | 0.09 | 0.07 | 0.04 |
| EPS Diluted | 15.45 | 17.64 | 19.46 | 15.98 | 9.17 | 7.24 | 5.59 | 5.09 | 4.92 | 4.71 | 3.48 | 3.21 | 3.46 | 2.53 | 2.01 | 2.25 | 1.72 | 0.84 | 1.36 | 2.17 | 1.20 | 1.73 | 0.00 | -0.22 | -1.10 | 1.08 | 1.41 | 1.22 | 0.99 | 0.82 | 0.29 | 0.17 | 0.16 | 0.13 | 0.10 | 0.09 | 0.09 | 0.07 | 0.04 |
| Weighted Avg Shares Out | 386.00M | 392.00M | 394.00M | 396.00M | 400.00M | 402.00M | 395.00M | 394.80M | 398.70M | 398.20M | 360.30M | 363.80M | 380.80M | 403.30M | 412.40M | 418.20M | 421.50M | 196.10M | 161.59M | 163.13M | 162.71M | 168.33M | 181.59M | 164.14M | 157.99M | 162.41M | 152.48M | 141.53M | 125.48M | 110.80M | 107.71M | 91.04M | 87.06M | 70.60M | 61.06M | 58.72M | 57.91M | 58.74M | 48.80M |
| Weighted Avg Shares Out (Dil) | 388.00M | 394.00M | 397.00M | 399.00M | 403.00M | 406.00M | 398.00M | 397.40M | 401.90M | 402.30M | 365.80M | 366.60M | 384.80M | 409.40M | 423.03M | 434.70M | 443.70M | 203.70M | 165.33M | 167.64M | 170.73M | 179.03M | 185.02M | 164.14M | 158.22M | 168.43M | 169.79M | 175.70M | 158.10M | 145.53M | 107.71M | 91.04M | 87.06M | 70.60M | 61.06M | 58.72M | 57.91M | 58.74M | 48.80M |
Thermo Fisher Scientific Launches International CorEvitas Clinical Registry in Adolescent Atopic Dermatitis, a Chronic Skin Condition
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of the international CorEvitas Adolescent Atopic Dermatitis (AD) Registry, designed to study novel treatments for the most common inflammatory skin condition in adolescent patients....
Thermo Fisher Scientific Expands Oral Solid Dose Development and Manufacturing Capabilities Across North America
CINCINNATI & BEND, Ore.--(BUSINESS WIRE)--To provide flexible and innovative solutions for early development challenges commonly faced by biotech and pharmaceutical companies, Thermo Fisher Scientific Inc. is expanding its oral solid dose (OSD) footprint with a $22-million total investment since 2021...
TMO Stock to Gain From Expanded Bioanalytical Services in Sweden
Thermo Fisher's PPD arm unveils a new facility in Sweden, expanding its bioanalytical capabilities.
Biognosys Enters Reselling Agreement for Spectronaut Proteomics Software with Leading Provider of Mass Spectrometry Systems
Biognosys' Spectronaut®, the leading vendor-agnostic software for DIA proteomics, is now directly available from Thermo Fisher Scientific under a reselling agreement End users can get access to Thermo Scientific mass spectrometry systems and Biognosys' Spectronaut software via a single offer...
Thermo Fisher Scientific (TMO) presents at Morgan Stanley 22nd Annual Global Healthcare Conference - Conference Call Transcript
Thermo Fisher Scientific (NYSE:TMO ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 8:30 AM ET Company Participants Marc Casper - Chairman, President and CEO Conference Call Participants Tejas Savant - Morgan Stanley Tejas Savant Hey, everyone. Good...
Why Is Thermo Fisher (TMO) Up 1.6% Since Last Earnings Report?
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?
Reasons to Retain Thermo Fisher (TMO) in Your Portfolio Now
Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).
Thermo Fisher Scientific Innovations Achieve R&D 100 Awards, including Special Recognition Market Disruptor
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, has received three R&D 100 Awards for innovations that aid researchers' and scientists' work in a variety of life science applications, including proteomics, bioproduction and small-molecule analysis. Notably,...
Thermo Fisher's (TMO) CDx Gets FDA's Nod for Synovial Sarcoma
Thermo Fisher Scientific TMO recently secured FDA's 510(k) clearance for its SeCore CDx HLA A Sequencing System for use as a companion diagnostic (CDx) alongside Adaptimmune's ADAP newly approved T-cell receptor (TCR) therapy, TECELRA (afamitresgene autoleucel). The latter is the...
Healthy Profits: 7 Healthcare Stocks to Build a Lifetime of Wealth
There are a whole host of reasons to invest in healthcare stocks over the long term. The United States has an aging population.
Source: https://incomestatements.info
Category: Stock Reports